Meet the speakers!

Ana B. Caballero Ana B. Caballero
Salvador Borrós Gómez Salvador Borrós Gómez
Marta Pérez Hernández Marta Pérez Hernández
Salvio Suárez García Salvio Suárez García
Elisabeth Engel Elisabeth Engel
Pere Santamaria i Vilanova Pere Santamaria i Vilanova
Daniel Closa Autet Daniel Closa Autet
Imma Ratera Imma Ratera

Ana B. Caballero

Dr. Ana B. Caballero earned her PhD in Chemistry from the Universidad de Granada (UGR-Spain) in 2010, with the highest qualification and UGR Award. During her PhD, she synthesized metal complexes with nucleobase mimetics and studies their structural, spectroscopic, magnetic and antiparasitic properties. Some of these compounds were patented as they showed great pharmaceutical interest (low cost and high efficacy in vivo; patent ES2436220A). She subsequently moved to UK to work with Prof. Mike Hannon as a postdoctoral fellow. During this period, she developed a new concept of anticancer drug design: DNA-interacting nanoparticles to enhance the antitumor efficacy of transported metallodrugs with controlled release. In 2014, she joined nanoBIC group at Universitat de Barcelona (UB), where she is the leader of the team Nano. Her current interests include the development of anti-Alzheimer and anti-cancer agents, anf the elucidation of the role of materials in amyloid-releated toxicity.

Salvador Borrós Gómez

Dr. Salvador Borrós i Gómez is the head of Materials Engineering group (GEMAT) and the general director of IQS-URL. He obtained his PhD in Chemical Engineering in IQS in 1993 and became Professor in 2004. He is also the founder member of the Heritage Conservation Technology Center (CETEC-Patrimoni).
Between 2009 and 2011, Dr. S. Borrós was the acting director of the Department of Industrial Engineering. Between 2015 and 2018 he was the director of the Department of Chemical Engineering and Material Science, and the Director of the Department of Bioengineering since 2018.
His main research lines are Material Science for heritage conservation; synthesis of NPs for controlled drug delivery; smart surfaces and scaffolds for tissue regeneration; polymeric materials for industrial applications and functional materials such as polymeric thin films and rapid manufacturing materials. He is currently leading a project called CoviNanoVax, based on looking for a vaccine for Covid19 of polymeric nanoparticles working as a vehicle to carry mRNA.

Marta Pérez Hernández

Dr. Marta Pérez Hernández holds a bachelor’s degree in Biochemistry, a Master degree in Molecular and Cellular Biology and a PhD in Biochemistry and Molecular Biology from Universidad de Zaragoza, Spain. Her predoctoral research was focused on the study of photothermal therapy (PTT) generated by gold nanoparticles as cancer treatment, working extensively on elucidating cell death mechanisms induced by PTT. She spent one year at University of Southern California (Los Angeles, USA) as a Postdoctoral researcher, where she increased her knowledge in the Cancer field working with cancer stem cells, studying metastasis in glioblastoma multiform. All this experience has provided her with a broad overview of the fields of Nanomedicine and Cancer. She joined Cancer Cell Biology research group in H. de Bellvitge (UB) in March 2018 and she is currently focused on the study of the encapsulation of novel anti-tumor drugs in a way that facilitates their accumulation into the tumor site with the goal of increasing their efficacy as well as decreasing the secondary effects commonly associated to chemotherapeutical agents.

Salvio Suárez García

Dr. Salvio Suárez García holds a PhD in Materials Science with specialization in Nanotechnology and Nanoscience. His thesis was focused on the development of novel materials for their application in thermochromism and bioimaging. He has been abroad (Vancouver, Vienna, Toulouse) establishing fruitful collaborations with expert groups in different areas. His expertise as a researcher is focused on the development of nanostructured functional materials and polymers (2D materials, coatings and nanoparticles) for their application in electronics and nanomedicine. His expertise covers from the chemistry in the lab, with the synthesis and characterization of the materials by different techniques, to the final applications (proof-of-concept devices for electronics and preclinical studies of novel theranostic agents, among others).

Elisabeth Engel

Dr. Elisabeth Engel got her PhD in 2003 in bone metabolism diseases in medical school. She was awarded with a postdoc fellow from the Ministry of Science at the Technical University of Catalonia in Biomaterials for bone tissue regeneration and since 2010 has been associate professor at this university. She was appointed principal investigator of the group of Biomaterials for Regenerative Therapies at IBEC in September 2012. Her research interests include the preparation and design of materials and scaffolds for in vitro and in vivo fundamental studies, and a further focus is the provision of useful tools to assess mechanisms that govern cell behavior in regenerative medicine. She has published around 80 papers in JRC journals and many invited lectures, and received an award for technological research (Barcelona City Award). Her group conducts several transference and translational projects with pharma and biomedical device industry partners, and participates actively in European projects.

Pere Santamaria i Vilanova

Dr. Pere Santamaria i Vilanova is  the head of the IDIBAPS group “Pathogenesis and treatment of autoimmunity“, and a professor of immunology and infectious diseases at the Faculty of Medicine of the University of Calgary. He is also the director of Julia McFarlane Diabetes Research Centre, Calgary. He graduated as Medical Doctor at the University of Barcelona in 1983, and did a MIR specialization in Immunology at the Bellvitge Hospital. He did a post-doc in genetic medicine at the University of Minnesota, Minneapolis. From the beginning of his career he has been devoted to the study of autoimmune diseases. In 2006 he founded the enterprise Parvus Therapeutics (Calgary, Canada), focused on developing therapeutics designed to halt and potentially cure autoimmune disease by restoring immune tolerance, showing amazing results for Diabetis I treatment. Between their most relevant projects, we find Navacim, a nanotechnology-based compound able to reprogram white blood cells to become regulatory cells capable of blunting autoimmune responses and restoring the equilibrium of the immune system. In 2019  Parvus Therapeutics  signed a worldwide collaboration and licence agreement with Genentech  to develop, manufacture and commercialise Navacim  therapeutics.

Daniel Closa Autet

Dr. Daniel Closa Autet is the head of the group “Molecular and cellular bases of inflammation. Structural and biological mass spectrometry” at IIBB-CSIC. He obtained a PhD in biology, and has been coordinating his work as a researcher with his interest in scientific divulgation. In 2004, he began writing its scientific blog “Centpeus”, with collaborations at the catalan newspaper “ARA”. In 2011 he won the “Blocs Catalunya” prize. He has also written many scientific books. In 1994 he won the “Premi Novel·la científica” with his book “Tots som parents”. In 2017 he won the prize “Sebastià Joan Arbó” with the book “El camí de la pesta”. He has also done collaborations  with several radio programmes as “Extraradi” (COM radi)  or “Gravetat zero” (Catalunya radio), and the TV programmes “Para todos la 2” or “A punto con la 2”. He recently published the book ‘100 coses que cal saber del virus’.

Imma Ratera

Dr. Imma Ratera, PhD in Materials Science (UAB) and Postdoc at the Surface Science Division of the Lawrence Berkeley National Laboratory (USA), is a Permanent Researcher at the Nanomol Department of the Institute of Materials Science of Barcelona (CSIC) since 2008. She is member of its scientific executive board and coordinator of the Biomaterials Research Line. She has served as Guarantee Researcher of the SO Centre of Excellence during 2016-2019. Her scientific interests include design, synthesis and processing of novel multifunctional molecular materials and biomaterials. Specifically, she is interested in the properties of these molecules once nanostructured as self-assembled monolayer (SAM), organic nanoparticle (ONP) or hydrogels towards applications in different fields such as molecular electronics, molecular magnetism, optoelectronics or as biomaterials for diagnosis, cell guidance or therapy among others. She has published around 100 articles, filled three patents and has been P.I. of several National and EU projects.